<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20160302162448+01'00'</creation_date><modification_date>D:20160302162448+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-03-269_h_a_dec_9.pdf</pdf_file></head><body><section><header>en  
   en</header><p>european 
 commission 
 brussels, 2.3.2016</p><p>c(2016) 1440 final</p></section><section><header>commission implementing decision of 2.3.2016 
 amending the marketing authorisation granted by decision c(2004)851 for “faslodex - 
 fulvestrant”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission implementing decision of 2.3.2016 
 amending the marketing authorisation granted by decision c(2004)851 for “faslodex - 
 fulvestrant”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by astrazeneca uk limited in accordance with regulation (ec) no 
 1234/2008, 
 having regard to the opinion of the european medicines agency, formulated on 26 march 
 2015 by the committee for medicinal products for human use, 
 whereas: 
 (1) 
 the european medicines agency&apos;s opinion is favourable to the variation of the terms 
 of the decision granting the marketing authorisation as submitted by the marketing 
 authorisation holder. 
 (2) 
 decision c(2004)851 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated. 
 (3) 
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2004)851 should therefore be replaced.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision: article 1 decision c(2004)851 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to astrazeneca uk limited, alderley park, macclesfield, cheshire, sk10 4tg united kingdom. 
 done at brussels, 2.3.2016</p><p>for the commission</p><p>
 xavier prats monné</p><p>
 director-general</p></section></body></xml>